title: Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections.
authors.affiliation: The Medicines Company, 7170 Frederick Banting, Ville Saint Laurent, Quebec, H4S 2A1, Canada. Electronic address: francis.arhin@themedco.com.
authors.forename: Francis F
authors.initials: FF
authors.lastname: Arhin
authors.affiliation: The Medicines Company, 7170 Frederick Banting, Ville Saint Laurent, Quebec, H4S 2A1, Canada.
authors.forename: Gregory
authors.initials: G
authors.lastname: Moeck
mesh_terms: D061605:Administration, Intravenous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002353:Carrier State / Q000382:microbiology*; D004311:Double-Blind Method; D024881:Drug Resistance, Bacterial; D006801:Humans; D000077427:Lipoglycopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009297:Nasal Mucosa / Q000382:microbiology*; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin